MedTrace Logo

Calcifediol in the Treatment of COVID 19

NCT05819918 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 728

Last updated 2023-04-28

No results posted yet for this study

Summary

Patients hospitalized with COVID-19 treated with calcifediol during the first outbreaks of the pandemic (until the first vaccinations) are compared with the aim of determining the therapeutic, clinical, functional, and biochemical variables that modify the response (admission to ICU or death) to calcifediol during hospitalization for COVID 19

Conditions

Interventions

DRUG

Calcifediol

Subjects hospitalized with COVID-19 treated with calcifediol

DRUG

Best available therapy

Subjects hospitalized with COVID-19 treated with Azithromycin, hydroxychloroquine, corticoids and others authorized treatments.

Sponsors & Collaborators

  • Maimónides Biomedical Research Institute of Córdoba

    lead OTHER

Principal Investigators

  • Luis M Entrenas Costa, MD · Hospital Universitario Reina Sofia de Cordoba

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-04-01
Primary Completion
2023-04-17
Completion
2023-04-17

Countries

  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05819918 on ClinicalTrials.gov